Medistem files patent application for stem-cell therapy to treat erectile dysfunction

By Elaine Rigoli

Tampa, Fla., Aug. 4 - Medistem Laboratories, Inc. said Friday that it filed a patent application with the U.S. Patent and Trademark Office for a potential stem-cell therapy for erectile dysfunction and other treatments.

The company said this market is approximately $3 billion per year.

Medistem said the invention could address the underlying physiological causes to restore erectile function, both by inhibiting disease processes as well as through regenerative activity to reverse damage to blood vessels, nerves and related cells.

Medistem is a biotechnology company based in Scottsdale, Ariz.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.